Focus and Scope
Cardiovascular Diagnosis and Therapy (CDT), is an international peer-reviewed journal that focuses on new basic and clinical research in Cardiovascular Medicine and Surgery. Aimed to promote rapid exchange of scientific information between clinicians and scientists worldwide and become a globally respected source of up-to-date information about all aspects of Cardiovascular Diagnosis and Therapy, the journal accepts basic and clinical science submissions related to Cardiovascular Medicine and Surgery. The editorial team is led by Paul Schoenhagen, Editor-in-Chief, and includes a highly respected international editorial board. With insightful and up-to-date editorials, reviews, perspectives, opinions, commentaries, research highlights, short communications and letters to the editor, CDT is being shaped into an international medical journal of great value in Cardiovascular field.
We welcome submissions of the following research areas but are not limited to:
1. Clinical Sciences:
- Clinical Cardiology
- Cardiothoracic and Cardiovascular Surgery
- Prevention and Rehabilitation
- Interventional Cardiology
- Heart Failure
- Imaging
- Electrophysiology
- Vascular Medicine (Stroke, PAD)
- Congenital Heart Disease
- Valvular heart disease
- Coronary artery diseas
2. Basic Sciences
- Genetics and Proteonomics
- Cell Biology/Signaling
- Atherosclerosis Research
- Stem Cell Research
- Nanotechnology
3. Other
- Epidemiology
- Outcome research and Cost Analysis
- Traditional Chinese medicine
- Cardiovascular Disease and Global Climate Change
- Cardiovascular Disease and Lifestyle
The website www.amepc.org/cdt will serve as the central hub and also allow posting of comments and on-line discussion. The web-site of the journal will be linked to a number of international web-sites, which will significantly expand the distribution of its contents.
DXY and MDLinx are two of them. DXY (http://www.dxy.cn/) is the largest online academic portal for five million Chinese physicians and life science professionals, with average daily page views of 1.8 millions. It was established in 2000, and now has over two million registered members. DXY features >100 columns to facilitate communication, information sharing and collaboration of medical professionals within practically all sub-specialties of clinical medicine, basic medical research, life sciences, and pharmaceutical sciences.
MDLinx (http://www.mdlinx.com/) is a practical medical information tool that busy physicians, healthcare professionals use to stay up to date with the latest research in the medical field. It aggregates medical articles, medical journals, medical newsletters and research from more than 1,200 peer-reviewed journals and leading news media on a daily basis. With its promotion, the readership of AMEPC journals would be largely expanded. Readers can also get access to other sister journals of the same research field through this portal.
Peer Review Process
Each submitted manuscript is evaluated for compliance with the following criteria:
• the potential interest of this topic to our readers
• strong evidence for the conclusions that are drawn
• novelty and originality
• broad biological or clinical significance
• contribution to the knowledge of a specific filed
A decision is made usually within six weeks of the receipt of the manuscript.
The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within four weeks of decision; major revisions within three months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.
A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.
Authors may recommend preferred reviewers by providing the Editor-in-Chief with the names, addresses and email addresses of up to three suitably qualified individuals of international standing but the Editor-in-Chief will not be bound by any such nomination. Likewise, authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief.
The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. Authors should write to the Editorial office.
All journals manuscripts should be written in a clear, concise, direct style, intelligible to the professional reader who is not necessarily a specialist in the particular field. Where contributions are judged as acceptable for publication, the Editor and the Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.
Open Access Policy
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.